Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2012

View Archived Issues

Takeda Pharmaceutical offers overview of third quarter fiscal 2011

BiondVax's phase II flu vaccine trial meets primary safety endpoint

Debiopharm commences phase Ib expansion study of Debio-0932

Hanmi and AngioLab enter licensing agreement

Studies point to benefit of sonothrombolysis after stroke

New antiviral agents disclosed by Alla Chem

Alla Chem presents new androgen receptor antagonists

Latvian company patents novel agents for influenza

New protein kinase inhibitors synthesized by Chinese team

Trials indicate ipilimumab can be administered with cancer vaccines

Novel tissue engineering scaffolds tested in vivo

Hyundai Pharmaceutical discloses new GPR119 receptor agonists

Novartis to revise product information for Rasilez in the E.U.

GlaxoSmithKline provides regulatory update on Tykerb/Tyverb

NeuroPhage Pharmaceuticals receives funding from Michael J. Fox Foundation

GlaxoSmithKline receives CHMP opinion on Nimenrix

Collaborating Japanese universities identify new potential target for cancer therapy

Gilead Sciences reports on ELECTRON trial

New approval for Zelboraf

Dainippon Sumitomo seeks line extension for Amlodin in Japan

EMA committee recommends conditional approval of Pixuvri

TCG Lifesciences chooses preclinical development candidate

CHMP recommends approval of Byetta line extension

FDA approves first medical therapy for endogenous Cushing's syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...